跳至主要内容
临床试验/NCT06004973
NCT06004973已完成不适用

Usability of STAR Particles in Healthy Volunteers: A Pilot Study

Emory University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年2月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
Transepidermal Water Loss (TEWL)

研究概览

简要总结

The objective of this study is to find out the best method of applying STAR particles to the skin. STAR particles are very small particles with microneedles on the surface that can increase and create small punctures in the skin.

The small punctures should allow for different topical medications to work more effectively. This is important to understand the potential use of STAR particles in future topical medications. This study will not use any medication with active ingredients.

The study will include healthy adult participants. The first visit will be to collect medical information and assess eligibility in the study. The second visit will have the application of STAR particles on different areas of the arm, hand, and face with different pressures to determine what the most effective method of application is. The skin will be evaluated after the application, and surveys will be collected on the tolerability of the application.

详细描述

The goal of this study is to identify the most efficacious pressure of administration and the minimum number of rubbing cycles necessary to perforate the stratum corneum (the outermost layer of the skin).

Many medical conditions are treated through the topical application of a therapeutic compound formulated into a gel, cream, ointment, or lotion (e.g., eczema, psoriasis, actinic keratosis, cutaneous warts). This is especially true in dermatology, in which the skin is often the primary site of action. Topicals (i.e., drugs applied to the skin's surface) allow patients to easily self-apply these therapies without the need for painful or difficult-to-use medical technologies (e.g., hypodermic needles) or the risks associated with systemic exposure to a drug (e.g., oral, intravenous, or intramuscular administration).

Despite the advantages associated with topical delivery, the skin serves as a barrier to the transport of most external compounds. There are several techniques to overcome the skin barrier. Several studies have been conducted to increase skin permeability using various methods, including chemical, biochemical, and physical approaches. However, chemical and biochemical methods do not appear to be broadly useful for the delivery of large molecule therapeutics (e.g., peptides, proteins, genetic material) across the skin. STAR particles are millimeter-scale particles with micron-scale projections made of biocompatible materials that painlessly disrupt the stratum corneum. As STAR particles are rubbed on the skin, their microscopic projections create micron-scale pores in the stratum corneum to increase skin permeability to topical compounds independent of physicochemical properties. After the arms of the STAR particle puncture the skin, the elastic forces of the skin push the particles out. The first 10 participants will receive the 8 interventions (different application pressures) plus the control (Site and treatment will not be randomly assigned to the arm) by the investigator. In addition, two applications of STAR particles will be applied to one of the hands. After these participants have completed the study, an interim analysis will be performed. At this point, a decision will be made by the investigator to determine if changes in STAR particle administration will be implemented for the next 10 participants.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 39 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Adult, 18 - 39 years of age
  • In good general health as determined by a medical history
  • Willing and able to provide informed consent and follow all study requirements
  • Not pregnant and does not desire to become pregnant in the subsequent two months

排除标准

  • Has a known allergy or sensitivity to aloe vera or alumina
  • Has any skin disorders or skin allergies
  • Has any medical condition that may affect skin or skin sensation
  • Has abnormal (e.g., tattooed) skin at forearms
  • Has known neurological condition affecting sensory function or perception of pain
  • Has inflammatory bowel disease
  • Has applied skin ointment or cream to forearms in the previous 24 hours
  • Has a major congenital or chromosomal abnormality known to affect the skin
  • Has taken pain medication in the last 24 hours
  • Is currently participating in another interventional clinical trial
  • Has previously participated in a STAR particle interventional clinical trial
  • Is pregnant or wishing to be pregnant
  • Has any condition (social or medical), which in the opinion of the investigator would make study participation unsafe, would interfere with adherence to the clinical study requirements, or would complicate data interpretation

研究组 & 干预措施

STAR Particles application

Experimental

Participants will receive the 8 interventions (different application pressures) plus the control (Site and treatment will not be randomly assigned on the arm) by the investigator.

干预措施: STAR Particles (Device)

Control Application

Other

Participants 1 to 10 will receive one control application on the volar side of one forearm.

Participants 11 to 20 will receive one control application on the opposite forearm and on the contralateral side of the face.

干预措施: Gel without STAR Particles (Device)

结局指标

主要结局

Transepidermal Water Loss (TEWL)

时间窗: Before application, 20 minutes after application, and 30 minutes after application

Trans-epidermal water loss (TEWL) measurement (only for the first 10 participants 1-10) before and after application of STAR particles \[(T0 (before), T20 (after), T30 (after)\].

次要结局

  • Sensation After Application of STAR Particles (Part 2 Only)(Immediately After STAR particles application)
  • Evaluate Pain Using the Visual Analog Pain Scale (VAPS) After Application of the STAR Particles (Part 2 Only)(Immediately After STAR particles application)
  • Number or Participants Who Reported Standard Adverse Event (AE)(Up to 5 days after the STAR particles removal (for a total of 5 days))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Eric Felner

Professor of Medicine

Emory University

研究点 (1)

Loading locations...

相似试验